Overview

A Randomized Study to Assess the Safety and Efficacy of Prograf vs Prograf-XL in de Novo Kidney Transplant Recipients

Status:
Completed
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the efficacy and safety of Prograf extended release(XL) plus MMF with Prograf plus MMF in de novo kidney transplant recipients.
Phase:
Phase 3
Details
Lead Sponsor:
Astellas Pharma Inc
Collaborator:
Astellas Pharma Taiwan, Inc.
Treatments:
Mycophenolate mofetil
Mycophenolic Acid
Tacrolimus